- Product
- Stockpiled COVID-19 drugs soon to expire in KOR
- by Kim JiEun Oct 23, 2024 05:49am
- A corona drug that caused a crisis due to its shortage has become a nuisance, an inventory glut, in just 3-4 months. In August, the government additionally distributed large quantities of the treatments, but the number of confirmed COVID-19 cases plummeted. The expiry date of the supply is approaching, raising the possibility of mass d
- Product
- Illegal errand companies deliver Wegovy for ₩10,000
- by Jung, Heung-Jun Oct 22, 2024 05:52am
- Amid the craze for obesity treatment drug Wegovy, errand companies are also thriving by offering pharmacy proxy pick-up and delivery services. These are illegal businesses that take advantage of the fact that consumers are looking for a low-priced source of the non-reimbursed drug, as the price varies greatly depending on the pharmacy.
- Product
- Consumers use tricks to receive Wegovy prescriptions
- by Kang, Hye-Kyung Oct 22, 2024 05:51am
- With heating interest in the obesity drug Wegovy, the way-around measures the consumers are taking to receive prescriptions are causing controversy. From how to receive Wegovy through non-face-to-face treatment venues without the legwork to how to split the high-dose formulations being shared online, concerns are growing over the drug’s
- Product
- Wegovy's price varies by pharmacy in Korea
- by Jung, Heung-Jun Oct 17, 2024 05:51am
- The price of Wegovy, which has been attracting much attention since its launch in Korea, has been found to vary greatly, ranging from KRW 420,000 to KRW 800,000. Some pharmacists who have not yet decided on the selling price are referring to the prices of in-house prescriptions at hospitals and local pharmacies. The prices of Wegovy at p
- Product
- ‘Disclose the pricing rationale used for COVID-19 drugs'
- by Kang, Hye-Kyung Oct 2, 2024 05:49am
- The Korean Pharmacists for Democratic Society (CEO Kyungrim Jeon, KPDS) has called for the disclosure of the cost-effectiveness evaluation results of the COVID-19 treatments Paxlovid and Veklury Inj. “The Ministry of Health and Welfare is engaging in the atrocity of setting excessive drug prices for COVID-19 treatments,” said the KPDS o
- Product
- Zomig distributor changes from AZ to SK Chemicals
- by Kim JiEun Sep 25, 2024 05:49am
- The distributor of Zomig Tab, a triptan used in the treatment of migraine, will change from AstraZeneca Korea to SK Chemical. The distribution industry suggests that the change in a distributor could impact the supply and demand chain. AstraZeneca Korea recently sent an official letter to the pharmaceutical wholesaler community of 'termina
- Product
- Concerns arise about securing COVID-19 treatment shortages
- by Kang, Hye-Kyung Aug 14, 2024 05:51am
- COVID-19 is spreading due to the circulating KP.3 variant. We have not learned lessons from the previous spread of the Omicron variant. As demand for test kits surges, there are no remaining stocks at online pharmacies. Even test kits with an expiration date within the end of October are no longer available. Due to shortages of oral medicine
- Product
- 92 patient groups implore doctors to stop the strike
- by Kang Hye-Kyung Jun 14, 2024 05:46am
- “We strongly demand the doctors withdraw their resolutions to take a collective leave of absence and indefinite leave of absence as they threaten the patients' lives and health." Ninety-two patient advocacy organizations have called for the withdrawal of the medical community's collective strike that is set to start on the 18th. Ninet
- Product
- Selection dilemma rises in IBD mkt due to increased options
- by Moon, sung-ho Jun 11, 2024 05:48am
- With the recent surge in treatment options for inflammatory bowel disease (IBD), which is represented by ulcerative colitis and Crohn's disease, developing an appropriate treatment strategy for IBD is emerging as a rising topic in clinical practice. This is due to the recent health insurance reimbursement extensions granted for treatments by
- Product
- Will Osimertinib emerge as the standard of care
- by Park, sang-jun Jun 10, 2024 05:41am
- The LAURA trial, which evaluated osimertinib’s effect in patients with unresectable Stage III EGFR-mutant non-small cell lung cancer who received chemoradiotherapy (CRT), was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also concurrently published in NEJM. The LAURA trial evaluated
